Transcranial direct current stimulation (tDCS) and consumer home neurostimulation occupy a complicated clinical space — established research efficacy in some indications, growing consumer market with mixed evidence quality, and patients increasingly asking clinicians about devices they have purchased or are considering. The clinical task is to engage the evidence honestly, recommend appropriately when the evidence supports use, and respond to patient queries with informed guidance.
The tDCS evidence in depression is modest but real. Meta-analyses of tDCS in depression show effect sizes smaller than TMS or medication but clinically meaningful in some studies. The technique applies low-intensity direct current (typically 1–2mA) through scalp electrodes over the dorsolateral prefrontal cortex; the mechanism appears to modulate cortical excitability through subthreshold neuronal polarization. Research protocols typically involve daily 20–30 minute sessions for several weeks. The Flow Neuroscience home device received CE marking in Europe and has FDA breakthrough device designation; the underlying evidence supports a clinical role though not as first-line.
Cognitive enhancement claims require skepticism. Many consumer tDCS devices market cognitive enhancement effects — focus, memory, learning, mood — based on heterogeneous research literature with mixed replication. Some legitimate signal exists in specific paradigms (motor learning enhancement, certain attention tasks); broader claims about durable cognitive enhancement in healthy adults are not well-supported. The patient who has purchased a home device based on cognitive enhancement claims deserves a frank conversation about the evidence quality.
Other home neurostimulation modalities. Transcranial alternating current stimulation (tACS), random noise stimulation (tRNS), and transcranial pulsed current stimulation each have research evidence in specific indications but less established clinical place than tDCS. Consumer devices increasingly combine modalities; the regulatory landscape varies. Wearable neurostimulation devices for headache (Cefaly), depression (Flow), and other indications have FDA clearance for specific uses.
The clinical recommendation framework. For depression: home tDCS may be reasonable for patients with mild-to-moderate depression who have inadequate access to standard treatment, prefer non-pharmacological approaches, or want adjunctive intervention. Not appropriate as substitute for evidence-based treatment in moderate-to-severe depression. For cognitive enhancement claims: recommend skepticism; the evidence does not support most marketing claims. For patients already using devices: respectful conversation about what evidence supports, what is speculation, what risks exist (minimal but not zero), what alternatives have stronger evidence.
The longevity-psychiatry frame. Home neurostimulation is not central to the cognitive-optimization prescription. The Modifiable Twelve factors — exercise, sleep, social engagement, cognitive engagement, BP/metabolic management — have substantially stronger evidence than any consumer neurostimulation device. The patient who is using a tDCS device but neglecting exercise, sleep, and other foundational factors is misallocating attention. The clinical conversation refocuses on the higher-leverage interventions. The discipline is to engage honestly with the evidence, recommend where it supports use, discourage where claims exceed evidence, and direct patient attention to the foundational interventions that produce the largest effects.